Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
HOME > BUSINESS
BUSINESS
- Santen Acquires Merck’s Eye Drugs in Japan, Key Markets
May 14, 2014
- 4 Major Wholesalers’ Average Operating Margin Tops 1% Mark, Signaling Biz Recovery
May 13, 2014
- Astellas FY2013 Sales Up 16% on Rosy Revenues from Xtandi, Betanis
May 13, 2014
- March Ethical Drug Sales Zoom 13.8% on Pre-Tax Hike Demand: Crecon Report
May 13, 2014
- Astellas Pres. “Aware” of Rumored Marriage with Daiichi Sankyo, but Denies Any Merger at This Time
May 13, 2014
- Questionnaire Survey of Chronic Myeloid Leukemia Patients Finds 30 Unreported ADRs: Novartis
May 13, 2014
- Nippon Kayaku Predicts Remicade Biosimilar Sales of 1.1 Billion Yen for FY2014
May 13, 2014
- MTPC Plans to Reduce Costs by 10 Billion Yen by FY2016
May 12, 2014
- FY2013 Japan Ethical Drug Market Crosses 10 Trillion Yen Mark for 1st Time: IMS
May 12, 2014
- Shionogi Makes Record Operating, Ordinary Profits
May 12, 2014
- LEO Pharma Takes Over Marketing Authorization to Dovonex
May 12, 2014
- Eisai to Develop Novel Inflammatory Bowel Disease Treatment with University of Tsukuba
May 12, 2014
- Kissei Aims to Maintain Non-Consolidated Sales, Launch Hyperphosphatemia Treatment: New Midterm Plan
May 12, 2014
- DSP to Execute Option Rights to Codevelop Cerebral Infarction Cell Therapy in April-Sept.
May 9, 2014
- MTPC to Push Tenelia, Canaglu to Compete in Diabetes Field
May 9, 2014
- DSP Sales Up 11.5% in FY2013; Latuda, Softer Yen Eclipse Japan Dip
May 9, 2014
- MTPC Logs 8.4% Net Profit Rise, 1.6% Sales Decline
May 9, 2014
- Takeda FY2013 Sales Up 8.6% on Buoyant Azilva, Pantoprazole
May 9, 2014
- Seikagaku to Initiate PII/III Clinical Trial of SI-614 for Treatment of Dry Eye in the US
May 9, 2014
- PII Study of Transdermal Allergic Rhinitis Treatment Confirms Significant Improvement in Primary Endpoint: Hisamitsu
May 9, 2014
ページ
The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…